Pelacarsen cut lipoprotein(a) by 78.4% at 12 months but did not reduce MACE vs placebo in 8322 patients with cardiovascular disease (HR, 1.02).
|Articles|September 16, 2008
- April15 2003
- Volume 10
- Issue 7
THE 50% CREDIT FLAG
Author(s)Michael Sheehan
Advertisement
Most lenders get leery when theysee credit card accounts or homeequity loans on your credit reportwith balances that are more than50% of the account limit. To avoidgetting tagged as a poorer credit riskthan you really are, ask your cardissuer to raise the limit on theaccount. If that doesn't work, thinkabout putting part of the debt onanother card. Be careful with the latteroption, though; lenders also don'tlike to see a lot of new applicationsfor credit cards on your report andwill downgrade you as a credit risk ifthey see too many.
Articles in this issue
about 18 years ago
Secure Tomorrow, Don't Lose Todayabout 18 years ago
Avoid the Turmoil of Insurance Mistakesabout 18 years ago
Bulletproof Your Car from the IRS' Aimabout 18 years ago
The PMD Answerman Q & Aabout 18 years ago
Impart Financial Values to Your Childrenabout 18 years ago
Watch Your Nest Egg's Financial Healthabout 18 years ago
Invest Some Land in Your 401(k) Accountabout 18 years ago
Plan According to Social Security Rulesabout 18 years ago
Discover Another Defined-Benefit Avenueabout 18 years ago
Know All Your Estate Planning BenefitsAdvertisement
Related to this article
Despite lowering free IL-6 and hsCRP, monthly ziltivekimab did not reduce 3-point MACE vs placebo in 6376 patients with ASCVD and CKD.
In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.
Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.
Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.
Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.
Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.
Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.
Advertisement
Advertisement
Trending on HCPLive
1
2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics
2
Noninvasive Models Underestimate CSPH in MASH Cirrhosis vs HVPG
3
Once-Monthly Efimosfermin Improves Fibrosis Markers in Phase 2 MASH Study
4
Lp(a) HORIZON Shows Pelacarsen Lowers Lp(a) 78% But Not Cardiovascular Events
5